Compare SLDB & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLDB | INSP |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2017 | 2018 |
| Metric | SLDB | INSP |
|---|---|---|
| Price | $8.11 | $50.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 16 |
| Target Price | $16.36 | ★ $94.00 |
| AVG Volume (30 Days) | ★ 1.2M | 858.3K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.97 | ★ 179.43 |
| EPS | N/A | ★ N/A |
| Revenue | $8,094,000.00 | ★ $82,050,000.00 |
| Revenue This Year | N/A | $8.02 |
| Revenue Next Year | N/A | $8.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 62.18 |
| 52 Week Low | $3.79 | $38.91 |
| 52 Week High | $11.45 | $147.03 |
| Indicator | SLDB | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 50.14 |
| Support Level | $6.25 | $48.30 |
| Resistance Level | $8.67 | $53.50 |
| Average True Range (ATR) | 0.45 | 2.22 |
| MACD | -0.16 | -0.38 |
| Stochastic Oscillator | 24.95 | 18.71 |
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.